Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Oct;25(10):1806-1807.
doi: 10.1002/ejhf.3022. Epub 2023 Sep 10.

Sodium-glucose cotransporter 2 inhibitors in hospitalized heart failure patients: No time like now

Rajat Kalra  1   2
Affiliations
Free article
Editorial

Sodium-glucose cotransporter 2 inhibitors in hospitalized heart failure patients: No time like now

Rajat Kalra. Eur J Heart Fail. 2023 Oct.
Free article
No abstract available

PubMed Disclaimer

Comment on

References

    1. Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial. Nat Med 2022;28:568-574. https://doi.org/10.1038/s41591-021-01659-1
    1. Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, et al. Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol 2019;73:2365-2383. https://doi.org/10.1016/j.jacc.2019.02.015
    1. Ferreira JP, Rossignol P, Machu JL, Sharma A, Girerd N, Anker SD, et al. Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: Findings from BIOSTAT-CHF. Eur J Heart Fail 2017;19:1284-1293. https://doi.org/10.1002/ejhf.900
    1. Ferreira JP, Blatchford JP, Teerlink JR, Kosiborod MN, Angermann CE, Biegus J, et al. Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE. Eur J Heart Fail 2023;25:1797-1805. https://doi.org/10.1002/ejhf.2982
    1. Shen L, Kristensen Søren L, Bengtsson O, Böhm M, de Boer RA, Docherty KF, et al. Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists. JACC Heart Fail 2021;9:254-264. https://doi.org/10.1016/j.jchf.2020.11.009

LinkOut - more resources